Is ORGO a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on CMS reimbursement reset and market adaptation, with revenue trajectory at Guided full-year 2026 net revenue sharply below record 2025, reflecting a projected double-digit percentage decline driven by CMS reimbursement and coverage changes. The bear case rests on the dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. Walnut is not an investment adviser.

CMS reimbursement reset and market adaptation. The finalized CY 2026 CMS payment reform for skin substitutes is the dominant near-term variable.

The dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025. Further coverage tightening, local coverage determinations, or continued market confusion over wastage could prolong the downturn or make recovery slower than management expects. The ReNu BLA carries regulatory risk because one of the two Phase 3 studies missed its primary endpoint, so approval and any eventual commercial ramp are far from guaranteed. As a small-cap in the middle of a business reset, ORGO is thinly valued, can be volatile, and faces execution risk on manufacturing, cost control, and cash. The Avista preferred stock and liquidation-preference terms add potential dilution and change-of-control considerations for common shareholders.

Organogenesis Holdings Inc.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (CMS reimbursement reset and market adaptation) stalling in the reported numbers rather than in the narrative, the risk above (the dominant risk is Medicare reimbursement policy: a large share of revenue depends on how CMS pays for skin substitutes, and the CY 2026 payment reform already drove a sharp advanced wound care revenue decline and a large cut to full-year guidance versus 2025) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is that 2026 is a transition year, the CMS reimbursement market eventually normalizes, and the ReNu knee osteoarthritis program opens a much larger market. The bear case is that a large share of revenue hinges on Medicare payment policy that just cut sharply, guidance fell steeply, and the ReNu Phase 3 data were mixed. Weigh both against your portfolio and consider that small-caps in a reset can be volatile.

Organogenesis is a regenerative medicine company that makes products to help the body heal. Its advanced wound care line includes skin substitutes and tissue-based products like Apligraf, PuraPly, and Affinity for chronic wounds such as diabetic foot ulcers and venous leg ulcers. Its surgical and sports medicine line includes ReNu and NuCel for soft-tissue healing. It sells to wound care clinics, hospitals, and physicians rather than directly to consumers.

The main driver was CMS reimbursement and coverage changes for skin substitutes under the CY 2026 fee schedule, which moved toward a per-square-centimeter payment method and created confusion in the market. Because much of Organogenesis's advanced wound care revenue is billed to Medicare, the policy shift disproportionately hit that segment, and the company guided full-year 2026 revenue well below its record 2025 result.